STOCK TITAN
  1. Home
  2. News
  3. DRNA

Dicerna Announces Novo Nordisk’s Nomination of First Candidate for Development Under RNAi Discovery and Development Agreement and Additional Milestone Achievement

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced Novo Nordisk A/S (“Novo”) has nominated its first candidate under the existing agreement between the two companies for the discovery and development of novel therapies for the treatment of liver-related cardiometabolic diseases using Dicerna’s proprietary GalXC™ RNAi platform technology.

“The past 12 months since closing our agreement with Novo have been extremely productive, with the identification and validation of multiple candidates under this highly collaborative relationship,” said Bob D. Brown, Executive Vice President and Head of Research and Development at Dicerna. “Tha

Stock DRNA logo
DRNA

NASDAQ:DRNA

DRNA Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

DRNA Latest News

Dec 28, 2021
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition
Dec 25, 2021
Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna
Nov 18, 2021
Novo Nordisk to Acquire Dicerna
Nov 12, 2021
Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lilly
Nov 12, 2021
Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021

DRNA Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Lexington

About DRNA

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using its proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna's GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, Dicerna has continued to innovate and is exploring new applications of its RNAi technology with GalXC-Plus, which expands on the functionality and application of its flagship liver-based GalXC technology, and has the potential to treat diseases across multiple therapeutic areas. In addition to its own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world's leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and its collaborative partners, they currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain. Dicerna's mission is to interfere - to silence genes, to fight disease, to restore health.